Lite Strategy (LITS) Times Interest Earned (2011 - 2026)
Lite Strategy (LITS) posted quarterly Times Interest Earned of -$25.79 for Q1 2026, down 409.43% year-over-year from $8.33 in Q1 2025, and up 26.52% quarter-over-quarter from -$35.1 in Q4 2025.
Lite Strategy (LITS) Times Interest Earned (2011 - 2026) Analysis & Trends
Lite Strategy's Times Interest Earned history runs 15 years deep, the most recent figure standing at -$25.79 for Q1 2026.
- In Q1 2026, Times Interest Earned fell 409.43% year-over-year to -$25.79; the TTM figure through Mar 2026 stood at -$25.93 (down 916.7% YoY), while the FY2025 annual figure was -$0.24, down 122.17% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$25.79, up from -$35.1 in the prior quarter.
- The five-year high for Times Interest Earned was $16.21 in Q3 2023, with the low at -$1246.3 in Q3 2025.
- The 5-year median for Times Interest Earned is -$16.83 (2024), against an average of -$87.41.
- The sharpest annual moves came in 2022 and 2023: Times Interest Earned sank 14692.6% in 2022, then jumped 1707.95% in 2023.
- Lite Strategy's Times Interest Earned stood at $2.16 in 2022, then slumped by 1049.11% to -$20.46 in 2023, then surged by 56.65% to -$8.87 in 2024, then slumped by 295.61% to -$35.1 in 2025, then gained by 26.52% to -$25.79 in 2026.
- Business Quant data shows LITS's Times Interest Earned at -$25.79 in Q1 2026, -$35.1 in Q4 2025, and -$1246.3 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.79 |
| Dec 31, 2025 | -35.10 |
| Sep 30, 2025 | -1,246.33 |
| Jun 30, 2025 | -0.04 |
| Mar 31, 2025 | -5.06 |
| Dec 31, 2024 | -8.87 |
| Sep 30, 2024 | -23.39 |
| Jun 30, 2024 | -1.60 |
| Mar 31, 2024 | -16.83 |
| Dec 31, 2023 | -20.46 |
| Sep 30, 2023 | 16.21 |
| Jun 30, 2023 | -19.54 |
| Mar 31, 2023 | -0.97 |
| Dec 31, 2022 | 2.16 |
| Sep 30, 2022 | -1.01 |
| Jun 30, 2022 | -42.62 |
| Mar 31, 2022 | -56.73 |
| Dec 31, 2021 | -5.12 |
| Sep 30, 2021 | -4.87 |
| Jun 30, 2021 | -0.29 |